Intermittent fasting doesn’t have an edge for weight loss, but might still work for some 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco 
Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production 
Time to buy local: war fuel price shocks reveal the folly of a long food supply chain 
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
ECB Eyes Rate Hike Amid Iran Conflict-Driven Energy Price Surge 
Bank of Japan Officials Signal Continued Interest Rate Hikes Amid Inflation Concerns 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
U.S. Stock Futures Steady as Iran Reviews U.S. Ceasefire Proposal 
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
Trump Tariffs Show Minimal Economic Impact but Boost Federal Revenue, Study Finds 
Oil Prices Climb as Iran Reviews U.S. Peace Proposal Amid Middle East Tensions 
SK bioscience Co. will invest $1.79 billion by 2027 to expand its contract manufacturing capabilities to strengthen its readiness for the next pandemic, expand its overseas operations, and seize new business opportunities.
The proposed investment is twice the amount the company had spent in the past five years.
Of the total investment, t half would be spent on research and development (R&D) and the construction of a new R&D campus in Songdo, Incheon, which is expected to be completed in 2025.
SK bioscience has manufactured the COVID-19 vaccines of AstraZeneca and Novavax in South Korea under a partnership deal.
The company is seeking to ink deals with major pharmaceutical companies within the year, according to SK bioscience CEO Ahn Jae-yong.
"A deal could come as early as within the first half of this year," he said.
Also, the company has been looking for a possible merger deal in the United States in the field of cell and gene therapy.
The company swung to a deficit for the January-March period as waning demand led to a drop in the production of licensed COVID-19 vaccines. Its loss amounted to 29.2 billion won, compared with a profit of 23.8 billion won a year ago.
Ahn expected the company to make a turnaround in three years after investing aggressively in building up the foundations for future growth.
